<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803816</url>
  </required_header>
  <id_info>
    <org_study_id>2006-004876-10</org_study_id>
    <nct_id>NCT00803816</nct_id>
  </id_info>
  <brief_title>Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A</brief_title>
  <official_title>Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carsten Heinz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Franziskus Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study efficacy of everolimus on course of uveitis:

        -  obtain quiescence of inflammation after start of treatment

        -  duration to obtain quiescence of inflammation

        -  number of patients with quiescence of inflammation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      occurence of new complications from uveitis

        -  course of visual acuity (LogMAR): percentage of patients with visual loss of 10 or more
           numbers on ETDRS as compared to baseline

        -  change of recurrence rate as compared to time before everolimus treatment

        -  occurence of recurrence after obtaining remission with everolimus treatment

        -  duration to occurence of recurrence o number of patients with recurrence

        -  corticosparing effect from everolimus

        -  number of patients without topical corticosteroids; number of patients with reduced
           topical corticosteroids (&lt;3x/daily)

        -  number of patients without systemic corticosteroids; number of patients with reduced
           systemic corticosteroids (&lt;10mg/daily)

        -  efficacy of uveitis within 12 months

        -  maintenance of remission after withdrawel of everolimus treatment at 12 months o course
           of cystoid macula edema (FLA, OCT)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inactivity of uveitis</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reoccurence of uveitis</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Uveitis</condition>
  <arm_group>
    <arm_group_label>Addition of everolimus to standard care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>refractive to cyclosporine A (CsA) received additional everolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>everolimus 1.0 - 2.5mg oral daily dosage</description>
    <arm_group_label>Addition of everolimus to standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  endogenous intermediate or posterior uveitis

          -  no quiesence in previous 3 months under systemic and topical steroids or systemic
             cyclosporine A

          -  indication for steroid sparing therapy

          -  uveitis related vision threating complications

          -  negative pregnancy test

          -  effective contraception

        Exclusion Criteria:

        Ophthalmic parameters:

          -  silicone oil in anterior chamber of both eyes para- or intraocular corticosteroid
             injections within previous 8 weeks

          -  opacities of optic media that obscure visualization of anterior or posterior eye
             segments

        General parameters:

          -  requirement for combined immunosuppression for systemic immune-mediated disease
             contraindication against everolimus or cyclosporine A

          -  positive tuberculine test (GT 10

          -  currently immunosuppressive therapy with immunosuppressive drug other than
             cyclosporine

          -  poor compliance

          -  known intolerance to medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnd Heiligenhaus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology at St. Franziskus Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology at St. Franziskus Hospital</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2008</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Franziskus Hospital</investigator_affiliation>
    <investigator_full_name>Carsten Heinz</investigator_full_name>
    <investigator_title>Prof Heiligenhaus Head of Department</investigator_title>
  </responsible_party>
  <keyword>endogoneous</keyword>
  <keyword>posterior</keyword>
  <keyword>intermediate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

